Dataset Information


The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome.

ABSTRACT: Antiphospholipid syndrome (APS) is characterized by thrombosis (arterial, venous, small vessel) and/or pregnancy morbidity occurring in patients with persistently positive antiphospholipid antibodies (aPL). Catastrophic APS is the most severe form of the disease, characterized by multiple organ thromboses occurring in a short period and commonly associated with thrombotic microangiopathy (TMA). Similar to patients with complement regulatory gene mutations developing TMA, increased complement activation on endothelial cells plays a role in hypercoagulability in aPL-positive patients. In mouse models of APS, activation of the complement is required and interaction of complement (C) 5a with its receptor C5aR leads to aPL-induced inflammation, placental insufficiency, and thrombosis. Anti-C5 antibody and C5aR antagonist peptides prevent aPL-mediated pregnancy loss and thrombosis in these experimental models. Clinical studies of anti-C5 monoclonal antibody in aPL-positive patients are limited to a small number of case reports. Ongoing and future clinical studies of complement inhibitors will help determine the role of complement inhibition in the management of aPL-positive patients.


PROVIDER: S-EPMC4805354 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6426753 | BioStudies
2019-01-01 | S-EPMC7382947 | BioStudies
2019-01-01 | S-EPMC6474283 | BioStudies
2020-01-01 | S-EPMC6978159 | BioStudies
2018-01-01 | S-EPMC6018396 | BioStudies
2019-01-01 | S-EPMC6514053 | BioStudies
2016-01-01 | S-EPMC6698865 | BioStudies
2013-01-01 | S-EPMC3625922 | BioStudies
2017-01-01 | S-EPMC5519006 | BioStudies
2015-01-01 | S-EPMC4877624 | BioStudies